Paul Tudor Jones's CSTL Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 222,982 shares of Castle Biosciences, Inc. (CSTL) worth $5.47 M, representing 0.01% of the portfolio. First purchased in 2021-Q1, this medium-term investment has been held for 14 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in CSTL, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 101,306 shares. Largest reduction occurred in Q2 2025, reducing 94,928 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Castle Biosciences (CSTL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Castle Biosciences (CSTL) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +55,804 | Add 33.38% | 222,982 | $24.55 |
| Q4 2025 | +81,743 | Add 95.68% | 167,178 | $38.90 |
| Q3 2025 | +8,981 | Add 11.75% | 85,435 | $22.77 |
| Q2 2025 | -94,928 | Reduce 55.39% | 76,454 | $20.42 |
| Q1 2025 | +101,306 | Add 144.57% | 171,382 | $20.02 |
| Q4 2024 | +20,586 | Add 41.60% | 70,076 | $26.65 |
| Q3 2024 | +15,552 | Add 45.82% | 49,490 | $28.52 |
| Q2 2024 | +20,941 | Add 161.12% | 33,938 | $21.77 |
| Q1 2024 | +12,997 | New Buy | 12,997 | $22.15 |
| Q1 2023 | -58,903 | Sold Out | 0 | $0.00 |
| Q4 2022 | +44,665 | Add 313.70% | 58,903 | $0.02 |
| Q3 2022 | +14,238 | New Buy | 14,238 | $26.06 |
| Q2 2021 | -3,101 | Sold Out | 0 | $0.00 |
| Q1 2021 | +3,101 | New Buy | 3,101 | $68.37 |
Paul Tudor Jones's Castle Biosciences Investment FAQs
Paul Tudor Jones first purchased Castle Biosciences, Inc. (CSTL) in Q1 2021, acquiring 3,101 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Castle Biosciences, Inc. (CSTL) for 14 quarters since Q1 2021.
Paul Tudor Jones's largest addition to Castle Biosciences, Inc. (CSTL) was in Q1 2025, adding 171,382 shares worth $3.43 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 222,982 shares of Castle Biosciences, Inc. (CSTL), valued at approximately $5.47 M.
As of the Q1 2026 filing, Castle Biosciences, Inc. (CSTL) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Castle Biosciences, Inc. (CSTL) was 222,982 shares, as reported at the end of Q1 2026.